BeOne Medicines (NASDAQ: ONC) counsel exercises options, sells 332 ADS under 10b5-1 plan

Rhea-AI Filing Summary

BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised employee share options covering 4,316 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96 per share. The options were represented as Share Options (Right to Buy) and convert into Ordinary Shares.

On the same date, he sold 332 American Depositary Shares at an average price of $310.72 per ADS in an open-market transaction made under a Rule 10b5-1 trading plan. Following these transactions, he directly owns 318,370 Ordinary Shares and no American Depositary Shares.

Insider Trade Summary 10b5-1

Net Seller: 332 shares ($103,159)

Net Sell 8 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 332 shs ($103K)

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	1,313	$0.00	--
Exercise	Share Option (Right to Buy)	1,729	$0.00	--
Exercise	Share Option (Right to Buy)	1,274	$0.00	--
Exercise	American Depositary Shares	101	$194.47	$20K
Exercise	American Depositary Shares	133	$213.32	$28K
Exercise	American Depositary Shares	98	$159.03	$16K
Sale	American Depositary Shares	332	$310.72	$103K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 19,864 shares (Direct, null); American Depositary Shares — 101 shares (Direct, null); Ordinary Shares — 318,370 shares (Direct, null)

Footnotes (1)

1. Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

ADS sold: 332 American Depositary Shares Sale price per ADS: $310.72 per ADS Options exercised (underlying shares): 4,316 Ordinary Shares +5 more

8 metrics

ADS sold 332 American Depositary Shares Open-market sale on May 13, 2026

Sale price per ADS $310.72 per ADS American Depositary Shares sale

Options exercised (underlying shares) 4,316 Ordinary Shares Total underlying shares from option exercises

Option exercise price 1 $12.23 per Ordinary Share Share Option exercise price

Option exercise price 2 $16.41 per Ordinary Share Share Option exercise price

Option exercise price 3 $14.96 per Ordinary Share Share Option exercise price

Ordinary Shares after transactions 318,370 Ordinary Shares Direct holdings following transactions

ADS to Ordinary ratio 1 ADS = 13 Ordinary Shares American Depositary Share representation

Key Terms

American Depositary Share, Rule 10b5-1 trading plan, Share Option (Right to Buy), exercise or conversion of derivative security, +1 more

5 terms

American Depositary Share financial

"Each American Depositary Share represents 13 Ordinary Shares."

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Share Option (Right to Buy) financial

"security_title: Share Option (Right to Buy)"

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

vest over a four-year period financial

"These securities vest over a four-year period as follows: 25% on the first anniversary..."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								318,370	D
American Depositary Shares(1)	05/13/2026		M		101	A	$194.47	101	D
American Depositary Shares(1)	05/13/2026		M		133	A	$213.32	234	D
American Depositary Shares(1)	05/13/2026		M		98	A	$159.03	332	D
American Depositary Shares(1)	05/13/2026		S(2)		332	D	$310.72	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(3)	05/13/2026		M			1,313	(4)	08/04/2032	Ordinary Shares	1,313	$0	19,864	D
Share Option (Right to Buy)	$16.41(3)	05/13/2026		M			1,729	(5)	06/14/2033	Ordinary Shares	1,729	$0	83,226	D
Share Option (Right to Buy)	$12.23(3)	05/13/2026		M			1,274	(6)	06/04/2034	Ordinary Shares	1,274	$0	107,848	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ONC executive Lee Chan Henry report?

Lee Chan Henry reported exercising employee share options into 4,316 Ordinary Shares, then selling 332 American Depositary Shares at $310.72 each. These transactions convert option-based compensation into shares and partial cash while leaving him with a substantial remaining Ordinary Share position.

How many BeOne Medicines (ONC) shares does Lee Chan Henry hold after these trades?

After the reported transactions, Lee Chan Henry directly holds 318,370 Ordinary Shares of BeOne Medicines Ltd. He reported no remaining American Depositary Shares, indicating his equity exposure is now concentrated in Ordinary Shares rather than ADS form.

Were the ONC insider share sales made under a Rule 10b5-1 plan?

Yes. The sale of 332 American Depositary Shares at $310.72 per ADS was effected pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged, reducing the significance of transaction timing as an indicator of the insider’s current view of the stock.

What option exercise prices did the ONC executive use in this Form 4?

The exercised Share Options carried exercise prices of $12.23, $16.41, and $14.96 per Ordinary Share. These options related to 1,274, 1,729, and 1,313 underlying Ordinary Shares respectively, reflecting different grant dates and vesting schedules described in the footnotes.

How many American Depositary Shares of ONC did the insider sell and at what price?

Lee Chan Henry sold 332 American Depositary Shares of BeOne Medicines at an average price of $310.72 per ADS. After this sale, his reported holdings of ADS fell to zero, while his ownership of Ordinary Shares remained significant.

What do the vesting terms of the ONC share options in this Form 4 look like?

The reported share options vest over four-year periods, with 25% vesting on a specified initial date and the remaining 75% vesting in 36 equal monthly installments. Continued service is required, and unvested options may vest early upon certain termination events described in the footnotes.